Andere Sprachen Pfizer Inc.

Aktien

852009

US7170811035

PFE

Pharmazeutika

Markt geschlossen - Nyse Andere Börsenplätze 22:05:04 22.04.2026			Vorbörslich 01:36:54
26,80 ^USD	-1,87 %		26,82	+0,09 %

00:06	Pfizer kündigt Dividende für das zweite Quartal 2026 an	RE
22.04.	Merck und Wettbewerber fürchten Inhibrx-Krebsmedikament im Visier - Synergien mit Keytruda im Fokus	RE

Andere Sprachen

22.04.	Pfizer Keeps Quarterly Dividend at $0.43 a Share, Payable June 12 to Shareholders of Record May 8
22.04.	Pfizer Declares Second-Quarter 2026 Dividend
22.04.	Los CDC de EEUU no publicarán informe que muestra eficacia de vacuna contra COVID-19
22.04.	Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say
22.04.	Pfizer GLP-1 weight loss drug available for pre-order in China
22.04.	US CDC will not publish report showing COVID vaccine effectiveness
21.04.	Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
21.04.	COVID shots, newer vaccines in limbo after US court halts Kennedy's advisory panel
20.04.	Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says
20.04.	Merck Announces FDA Grants Priority Review For Keytruda And Keytruda Qlex Each With Padcev For Cisplatin-Eligible Patients With Muscle-Invasive Bladder Cancer
20.04.	Pfizer's Upcoming Tafamidis Bench Trial Shows Asymmetric Upside, RBC Capital Markets Says
20.04.	Astellas Pharma Inc. And Pfizer Inc. Receive U.S. FDA Priority Review For PADCEV And Keytruda As Perioperative Treatment For Muscle-Invasive Bladder Cancer
20.04.	Merck, Pfizer, Astellas Drug Combo Gets Speedy FDA Review in Bladder Cancer
20.04.	Merck Says FDA Grants Priority Review to Keytruda-Padcev Combo for Bladder Cancer
20.04.	U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
20.04.	Pfizer, Amgen Eyeing Hong Kong Expansion
16.04.	Harbour Biomed Appoints Adam Zong as President
16.04.	DND Pharmatech Wins KRW1.83 Billion Anti-Obesity Drug Formulation Contract from Pfizer; Shares Rise 3%
14.04.	Structure Therapeutics Names Matthew Lang as COO
14.04.	Pharma sector doubles down on AI amid hopes of slashing costs, timelines
13.04.	Lineage Cell Therapeutics, Inc. Announces Formation of Scientific Advisory Board and Executive Appointment
13.04.	Temporada de resultados a la sombra de Trump
13.04.	Orum Therapeutics, Inc. Appoints Maria Koehler and Geoff Meyerson to Board of Directors
13.04.	Earnings Season in Trump's Shadow
13.04.	Pfizer Renews Licensing Deal With Trellus Health for Patient Support Educational Content